GYRE · Company research
Gyre Therapeutics, Inc. Common Stock (GYRE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Gyre Therapeutics stock falls 5.00 percent to USD 6.08 on October 16, 2026 - ad-hoc-news.de | Gyre Therapeutics stock falls 5.00 percent to USD 6.08 on October 16, 2026 ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 17, 2026 | neutral | 0 | 0.6 |
| (GYRE) and the Role of Price-Sensitive Allocations - Stock Traders Daily | (GYRE) and the Role of Price-Sensitive Allocations Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 16, 2026 | neutral | 0 | 0.6 |
| H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock - ad-hoc-news.de | H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 15, 2026 | neutral | 0 | 0.6 |
| Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Stocktwits | Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead Stocktwits | View source ↗ | Stocktwits | Oct 10, 2026 | neutral | 0 | 0.6 |
| H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock - AD HOC NEWS | H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock AD HOC NEWS | View source ↗ | AD HOC NEWS | Oct 6, 2026 | neutral | 0 | 0.6 |
| Trading the Move, Not the Narrative: (GYRE) Edition - Stock Traders Daily | Trading the Move, Not the Narrative: (GYRE) Edition Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 6, 2026 | neutral | 0 | 0.6 |
| Gyre Therapeutics (Nasdaq:GYRE) - Stock Analysis - Simply Wall Street | Gyre Therapeutics (Nasdaq:GYRE) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| GYRE Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on Shares - Tax Rate Impact - dars.gov.et | GYRE Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on Shares - Tax Rate Impact dars.gov.et | View source ↗ | dars.gov.et | Sep 29, 2026 | neutral | 0 | 0.6 |
| GYRE Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on Shares - Estimate Uncertainty - https://www.dars.gov.et/ | GYRE Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on Shares - Estimate Uncertainty https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Sep 29, 2026 | neutral | 0 | 0.6 |
| (GYRE) Volatility Zones as Tactical Triggers - Stock Traders Daily | (GYRE) Volatility Zones as Tactical Triggers Stock Traders Daily | View source ↗ | Stock Traders Daily | Sep 26, 2026 | neutral | 0 | 0.6 |
| Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 Resistance - McClellan Summation - siam.in | Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 Resistance - McClellan Summation siam.in | View source ↗ | siam.in | Aug 20, 2026 | neutral | 0 | 0.6 |
| About $300M Cullgen deal adds cancer candidates to Gyre's pipeline - Stock Titan | About $300M Cullgen deal adds cancer candidates to Gyre's pipeline Stock Titan | View source ↗ | Stock Titan | Aug 7, 2026 | neutral | 0 | 0.6 |
| Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance | Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 7, 2026 | neutral | 0 | 0.6 |
| Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy - The Globe and Mail | Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy The Globe and Mail | View source ↗ | The Globe and Mail | Jun 3, 2026 | neutral | 0 | 0.6 |
| US High Growth Tech Stocks To Watch - Simply Wall Street | US High Growth Tech Stocks To Watch Simply Wall Street | View source ↗ | Simply Wall Street | May 28, 2026 | neutral | 0 | 0.6 |
| Gyre Therapeutics acquires Cullgen in $300M all-stock deal - Dealroom | Gyre Therapeutics acquires Cullgen in $300M all-stock deal Dealroom | View source ↗ | Dealroom | May 15, 2026 | neutral | 0 | 0.6 |
| Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction - Yahoo Finance | Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction Yahoo Finance | View source ↗ | Yahoo Finance | Mar 3, 2026 | neutral | 0 | 0.6 |
| Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout - Fierce Biotech | Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout Fierce Biotech | View source ↗ | Fierce Biotech | Mar 2, 2026 | neutral | 0 | 0.6 |
| Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire | Gyre Therapeutics Enters into Agreement to Acquire Cullgen GlobeNewswire | View source ↗ | GlobeNewswire | Mar 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.